x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Few & Far Between: How Biotech Gets Built

Welcome to Few & Far Between! Chris O"Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.

science life sciences

All Episodes

00:44:53

Episode 57: Jim Brown, DVM, President and CEO of...

Few & Far Between: How Biotech Gets Built ·

2025/07/22

Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jim Brown, President and CEO of DURECT Corporation, for a conversation on the importance of a pharmacoeconomic strategy, developing new treatments for alcohol associated hepatitis, and moving beyond what a single individual can do in clinical research. Tune in today!

en

00:39:28

Episode 56, Part Two: Michael Tolentino, MD,...

Few & Far Between: How Biotech Gets Built ·

2025/07/15

How do experienced troubleshooters solve a difficult problem? By asking the right questions first! Welcome back to part two of our conversation with Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics. Join host Chris O'Brien as he and Dr. Tolentino, explore the traits of top problem solvers, the power of communication, and how silos and "bad apples" can undermine today's biotechs. Okay, let's start the podcast!

en

00:39:28

Episode 56, Part Two: Michael Tolentino, MD,...

Few & Far Between: How Biotech Gets Built ·

2025/07/15

How do experienced troubleshooters solve a difficult problem? By asking the right questions first! Welcome back to part two of our conversation with Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics. Join host Chris O'Brien as he and Dr. Tolentino, explore the traits of top problem solvers, the power of communication, and how silos and "bad apples" can undermine today's biotechs. Okay, let's start the podcast!

en

00:38:46

Episode 55: Julio G. Martinez-Clark, CEO and...

Few & Far Between: How Biotech Gets Built ·

2025/07/09

How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this region. In our latest episode of the Biorasi Few & Far Between podcast, host Chris O'Brien welcomes Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®. Tune in as we spotlight the advantages of running studies in #LATAM - from data quality to speed to approval.

en

00:38:46

Episode 55: Julio G. Martinez-Clark, CEO and...

Few & Far Between: How Biotech Gets Built ·

2025/07/09

How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this region. In our latest episode of the Biorasi Few & Far Between podcast, host Chris O'Brien welcomes Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®. Tune in as we spotlight the advantages of running studies in #LATAM - from data quality to speed to approval.

en

00:45:11

Episode 54, Part One: Michael Tolentino, MD,...

Few & Far Between: How Biotech Gets Built ·

2025/05/28

The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics, to the podcast. Tune in to part one of this special two-part episode as we explore Michael's start in ophthalmology, groundbreaking treatments in intra-retinal therapy, and the importance of

en

00:45:11

Episode 54, Part One: Michael Tolentino, MD,...

Few & Far Between: How Biotech Gets Built ·

2025/05/28

The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics, to the podcast. Tune in to part one of this special two-part episode as we explore Michael's start in ophthalmology, groundbreaking treatments in intra-retinal therapy, and the importance of

en

00:50:46

Episode 53: Frank David, Founder and Managing...

Few & Far Between: How Biotech Gets Built ·

2025/04/29

How do mission, vision, and data analysis fit into today's biotech goals? Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan to the podcast. Tune in as we explore R&D strategy, de-risking tactics, and how to think about valuation. Listen in to the latest episode of the Biorasi Few & Far Between podcast today!

en

00:50:46

Episode 53: Frank David, Founder and Managing...

Few & Far Between: How Biotech Gets Built ·

2025/04/29

How do mission, vision, and data analysis fit into today's biotech goals? Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan to the podcast. Tune in as we explore R&D strategy, de-risking tactics, and how to think about valuation. Listen in to the latest episode of the Biorasi Few & Far Between podcast today!

en

00:52:05

Episode 52: Joshua Kresh, Emily Michiko Morris, and...

Few & Far Between: How Biotech Gets Built ·

2025/04/23

How does a biotech balance great science with IP security to tell their story? Find out on today's episode of the Few & Far Between podcast! Host Chris O'Brien welcomes Joshua Kresh, Emily Michiko Morris, and Mark Schultz from IPPI: The Intellectual Property Policy Institute. Tune in for a fascinating discussion on the dos and don'ts of IP protection. Listen to the latest episode today!

en

00:52:05

Episode 52: Joshua Kresh, Emily Michiko Morris, and...

Few & Far Between: How Biotech Gets Built ·

2025/04/23

How does a biotech balance great science with IP security to tell their story? Find out on today's episode of the Few & Far Between podcast! Host Chris O'Brien welcomes Joshua Kresh, Emily Michiko Morris, and Mark Schultz from IPPI: The Intellectual Property Policy Institute. Tune in for a fascinating discussion on the dos and don'ts of IP protection. Listen to the latest episode today!

en

00:55:05

Episode 51: Dan Oliver, CEO and Founder, Rejuvenate Bio

Few & Far Between: How Biotech Gets Built ·

2025/04/03

How do you turn back the epigenetic clock for humans and their animal companions? Host Chris O'Brien welcomes Dan Oliver, CEO and Founder of Rejuvenate Bio, to the podcast. Tune in as we take a deep dive into parallel clinical trials designed to address chronic, age-related diseases in people and their pets. Plus, we'll zoom in on the right corporate structure for biotech products and the benefits of brainstorming. Listen in to the latest episode of the

en

00:55:05

Episode 51: Dan Oliver, CEO and Founder, Rejuvenate Bio

Few & Far Between: How Biotech Gets Built ·

2025/04/03

How do you turn back the epigenetic clock for humans and their animal companions? Host Chris O'Brien welcomes Dan Oliver, CEO and Founder of Rejuvenate Bio, to the podcast. Tune in as we take a deep dive into parallel clinical trials designed to address chronic, age-related diseases in people and their pets. Plus, we'll zoom in on the right corporate structure for biotech products and the benefits of brainstorming. Listen in to the latest episode of the

en

00:52:02

Epsiode 50: Jonathan Rigby, Chairman and CEO, Sernova

Few & Far Between: How Biotech Gets Built ·

2025/03/18

Now on the Few & Far Between podcast: Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia? Today's guest, who has TD1, explains how he turned his passion for helping others into innovative treatments for diabetes and other chronic diseases. Host Chris O'Brien welcomes Jonathan Rigby, Chairman and CEO at Sernova, to the podcast. Listen in as we spotlight Jonathan's 30-year industry journey, the development of

en

00:52:02

Epsiode 50: Jonathan Rigby, Chairman and CEO, Sernova

Few & Far Between: How Biotech Gets Built ·

2025/03/18

Now on the Few & Far Between podcast: Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia? Today's guest, who has TD1, explains how he turned his passion for helping others into innovative treatments for diabetes and other chronic diseases. Host Chris O'Brien welcomes Jonathan Rigby, Chairman and CEO at Sernova, to the podcast. Listen in as we spotlight Jonathan's 30-year industry journey, the development of implantable bio-hybrid organs, and

en

00:35:37

Episode 49: Eileen Faucher, Principal and Founder,...

Few & Far Between: How Biotech Gets Built ·

2025/02/27

Today on the Biorasi Few & Far Between podcast: What if you could read a story before its official release? Competitive intelligence gives you early access to information on emerging trends in clinical trials. On today's episode, host Chris O'Brien welcomes Eileen Faucher. Eileen is the Principal and Founder of Brass Tacks Health, a company that provides insights that biotechs need to drive clinically-meaningful therapies. Listen in to get the ROI on competitive

en

00:35:37

Episode 49: Eileen Faucher, Principal and Founder,...

Few & Far Between: How Biotech Gets Built ·

2025/02/27

Today on the Biorasi Few & Far Between podcast: What if you could read a story before its official release? Competitive intelligence gives you early access to information on emerging trends in clinical trials. On today's episode, host Chris O'Brien welcomes Eileen Faucher. Eileen is the Principal and Founder of Brass Tacks Health, a company that provides insights that biotechs need to drive clinically-meaningful therapies. Listen in to get the ROI on competitive

en

00:38:46

Episode 48: John Celebi, President and CEO, Sensei Bio

Few & Far Between: How Biotech Gets Built ·

2025/02/18

"You have to have the right people, the right team, and good science." - John Celebi, President and CEO, Sensei Bio Welcome back to Biorasi's Few & Far Between podcast. On today's episode, host Chris O'Brien welcomes John Celebi to the pocast. Be sure to tune in for insights into assembling a core management team and how to build openness and inclusivity into biotech company culture. Thank's for listening!

en

00:43:29

Episode 46: Ben Olds and Amy Fenollosa, Haven Human...

Few & Far Between: How Biotech Gets Built ·

2025/01/15

"There's that old saying, 'culture is how people behave when nobody's looking.' So, if you want to be effective, your [mission and value statements] have to be specific enough to actually guide behavior." - Ben Olds, Executive Coach and Managing Partner, Haven Human Asset Ventures Welcome back to Biorasi's Few & Far Between podcast. On today's episode, host Chris O'Brien welcomes Ben Olds and Amy Fenollosa from Haven Human Asset Ventures. Tune in for an in-depth discussion

en

00:43:29

Episode 46: Ben Olds and Amy Fenollosa, Haven Human...

Few & Far Between: How Biotech Gets Built ·

2025/01/15

"There's that old saying, 'culture is how people behave when nobody's looking.' So, if you want to be effective, your [mission and value statements] have to be specific enough to actually guide behavior." - Ben Olds, Executive Coach and Managing Partner, Haven Human Asset Ventures Welcome back to Biorasi's Few & Far Between podcast. On today's episode, host Chris O'Brien welcomes Ben Olds and Amy Fenollosa from Haven Human Asset Ventures. Tune in for an in-depth discussion

en

121 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter